Kamal A. Saeed

Array ( [id] => 20627750 [patent_doc_number] => 20260092034 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-04-02 [patent_title] => 7-AZAINDOLE ANALOGS AND METHODS OF TREATING NEUROLOGICAL DISORDERS USING THE SAME [patent_app_type] => utility [patent_app_number] => 19/412382 [patent_app_country] => US [patent_app_date] => 2025-12-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79661 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19412382 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527221 [patent_doc_number] => 12545645 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Crystalline salts of a plasma kallikrein inhibitor [patent_app_type] => utility [patent_app_number] => 19/312645 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7374 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20622572 [patent_doc_number] => 12590069 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Crystalline salts of a plasma kallikrein inhibitor [patent_app_type] => utility [patent_app_number] => 19/313046 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7272 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19313046 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20407338 [patent_doc_number] => 20250376447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITOR [patent_app_type] => utility [patent_app_number] => 19/312656 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7159 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312656 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20622571 [patent_doc_number] => 12590068 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-03-31 [patent_title] => Crystalline salts of a plasma kallikrein inhibitor [patent_app_type] => utility [patent_app_number] => 19/313010 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7570 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19313010 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527222 [patent_doc_number] => 12545646 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Crystalline salts of a plasma kallikrein inhibitor [patent_app_type] => utility [patent_app_number] => 19/312755 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7231 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312755 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20527223 [patent_doc_number] => 12545647 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-10 [patent_title] => Crystalline salts of a plasma kallikrein inhibitor [patent_app_type] => utility [patent_app_number] => 19/312786 [patent_app_country] => US [patent_app_date] => 2025-08-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 7560 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19312786 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20701334 [patent_doc_number] => 12624034 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-12 [patent_title] => Non-covalent modifiers of AKT1 and uses thereof [patent_app_type] => utility [patent_app_number] => 19/225802 [patent_app_country] => US [patent_app_date] => 2025-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 93616 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 1044 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19225802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20219791 [patent_doc_number] => 20250282722 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => 7-METHYL INDOLE ANALOGS AND DOSAGE FORMS CONTAINING THE SAME [patent_app_type] => utility [patent_app_number] => 19/215938 [patent_app_country] => US [patent_app_date] => 2025-05-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79859 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19215938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19909227 [patent_doc_number] => 12285412 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-04-29 [patent_title] => Organoselenium benzimidazole compounds for treating cancer [patent_app_type] => utility [patent_app_number] => 19/003381 [patent_app_country] => US [patent_app_date] => 2024-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 5841 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19003381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20049821 [patent_doc_number] => 20250188043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-06-12 [patent_title] => LEFLUTROZOLE COMPOSITIONS OF MATTER AND PROCESSES FOR PREPARATION [patent_app_type] => utility [patent_app_number] => 18/973849 [patent_app_country] => US [patent_app_date] => 2024-12-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26909 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18973849 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19846640 [patent_doc_number] => 20250091991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => MIXED SEROTONIN 5-HT2A/2C RECEPTOR AGONISTS AND METHODS FOR TREATING PAIN AND DEPRESSION [patent_app_type] => utility [patent_app_number] => 18/968441 [patent_app_country] => US [patent_app_date] => 2024-12-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 83692 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18968441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19666086 [patent_doc_number] => 12178806 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2024-12-31 [patent_title] => Method for contacting cancer cells with antitumor agent and apoptotic inducer [patent_app_type] => utility [patent_app_number] => 18/799676 [patent_app_country] => US [patent_app_date] => 2024-08-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 7512 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18799676 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19586328 [patent_doc_number] => 20240383885 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-21 [patent_title] => Compounds for Treating Cannabinoid Toxicity and Acute Cannabinoid Overdose [patent_app_type] => utility [patent_app_number] => 18/779153 [patent_app_country] => US [patent_app_date] => 2024-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29906 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 9729 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18779153 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541827 [patent_doc_number] => 20240358863 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => COMPLEX OF GADOLINIUM AND A CHELATING LIGAND DERIVED FROM A DIASTEREOISOMERICALLY ENRICHED PCTA AND PREPARATION AND PURIFICATION PROCESS [patent_app_type] => utility [patent_app_number] => 18/766792 [patent_app_country] => US [patent_app_date] => 2024-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15315 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18766792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745543 [patent_doc_number] => 20250034108 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => SODIUM CHANNEL BLOCKERS [patent_app_type] => utility [patent_app_number] => 18/764471 [patent_app_country] => US [patent_app_date] => 2024-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19724008 [patent_doc_number] => 20250026759 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-23 [patent_title] => TETRAHYDROQUINAZOLINE DERIVATIVES AS SELECTIVE CYTOTOXIC AGENTS [patent_app_type] => utility [patent_app_number] => 18/764441 [patent_app_country] => US [patent_app_date] => 2024-07-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31346 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 226 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764441 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19745591 [patent_doc_number] => 20250034156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza [patent_app_type] => utility [patent_app_number] => 18/764058 [patent_app_country] => US [patent_app_date] => 2024-07-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28687 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764058 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19526611 [patent_doc_number] => 20240350513 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => APPLICATIONS OF CX-5461 IN TREATING IMMUNE REJECTION IN RENAL TRANSPLANTATION [patent_app_type] => utility [patent_app_number] => 18/761482 [patent_app_country] => US [patent_app_date] => 2024-07-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18761482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743897 [patent_doc_number] => 20250032462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => BAX ACTIVATORS AND USES THEREOF IN CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 18/752081 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18752081 [rel_patent_id] =>[rel_patent_doc_number] =>)